Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
1
20%
Ph phase_3
1
20%
Ph phase_1
1
20%
Ph not_applicable
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

completed360%
recruiting120%
withdrawn120%

Recent Activity

1 active trials
Showing 5 of 5
recruiting

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436
completedphase_1

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

NCT00789685
completednot_applicable

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

NCT00004450
withdrawnphase_4

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

NCT02234869
completedphase_3

Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis

NCT00344253

Clinical Trials (5)

Showing 5 of 5 trials
NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting
NCT00789685Phase 1

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

Completed
NCT00004450Not Applicable

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Completed
NCT02234869Phase 4

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

Withdrawn
NCT00344253Phase 3

Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5